Mineralys Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mineralys Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2022 to 2023.
  • Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$56.3M, a 148% decline year-over-year.
  • Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$153M, a 171% decline year-over-year.
  • Mineralys Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.9M, a 141% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$71.9M -$42.1M -141% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$29.8M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.